Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bristol Dental School, University of Bristol, Bristol, United Kingdom.
Oral Oncol. 2020 Aug;107:104721. doi: 10.1016/j.oraloncology.2020.104721. Epub 2020 Apr 30.
To compare risk factors and survival in people with oropharyngeal cancer (OPC) and cancer unknown primary (CUP).
We recruited 5511 people with head and neck cancer between 2011 and 2014. We collected data on age, gender, smoking, sexual behaviour, treatment intent, stage, co-morbidity, p16 protein overexpression and biological samples. We assessed human papillomavirus (HPV) status using serological response and p16 immunohistochemistry. We followed up participants to identify those who had died. We used Cox proportional hazards regression models to estimate survival and adjust for confounders.
Of the 4843 people with squamous cell cancer 196 had CUP - a prevalence of 4.0% (95% CI 3.5% to 4.6%). Of those people with OPC and CUP 69% (1150/1668) and 60% (106/178) respectively had HPV driven tumours. People with HPV driven tumours were likely to be younger, male, non-smokers, with higher stage disease, a history of oral sex and less co-morbidity. People with HPV negative CUP and HPV driven CUP had the survival of people with a stage II/III HPV negative OPC and a stage I/II HPV driven OPC respectively. The adjusted hazard ratio for HPV driven OPC and CUP compared with HPV negative OPC and CUP was 0.46 (95% CI 0.35 to 0.59) and 0.34 (95% CI 0.14 to 0.82) respectively.
HPV driven CUP is likely to be HPV driven OPC. Identifying effective methods of detecting occult OPC could improve CUP management and allow the detection of early lesions in high risk groups.
比较口咽癌(OPC)和不明原发灶癌(CUP)患者的危险因素和生存情况。
我们招募了 2011 年至 2014 年间的 5511 名头颈部癌症患者。收集了年龄、性别、吸烟、性行为、治疗意图、分期、合并症、p16 蛋白过表达和生物样本等数据。我们使用血清学反应和 p16 免疫组化来评估人乳头瘤病毒(HPV)状态。我们对参与者进行随访以确定死亡者。我们使用 Cox 比例风险回归模型来估计生存情况并调整混杂因素。
在 4843 名患有鳞状细胞癌的患者中,有 196 人患有 CUP,患病率为 4.0%(95%CI 3.5%至 4.6%)。在 OPC 和 CUP 患者中,分别有 69%(1150/1668)和 60%(106/178)的人患有 HPV 驱动的肿瘤。HPV 驱动肿瘤的患者更年轻、男性、不吸烟、疾病分期更高、有口交史和合并症较少。HPV 阴性 CUP 和 HPV 驱动的 CUP 患者的生存情况分别与 HPV 阴性 OPC 的 II/III 期和 HPV 驱动的 OPC 的 I/II 期相似。HPV 驱动的 OPC 和 CUP 与 HPV 阴性 OPC 和 CUP 相比的调整后的危险比分别为 0.46(95%CI 0.35 至 0.59)和 0.34(95%CI 0.14 至 0.82)。
HPV 驱动的 CUP 可能是 HPV 驱动的 OPC。识别检测隐匿性 OPC 的有效方法可能改善 CUP 的管理,并允许在高危人群中检测早期病变。